Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziv-aflibercept in Metastatic Renal Cell Carcinoma
NCT00357760Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2007
- Primary completion
- Oct 2015
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of aflibercept in renal cell carcinoma (RCC), sponsored by National Cancer Institute. Started Dec 2007; status: completed.
02
Drugs
aflibercept
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00357760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00357760.